Drug Database
BO

botulinum toxin type A + hemagglutinin (Relatox / Relatoks)

✓ Approved

Microgen · 治疗药物

什么是 botulinum toxin type A + hemagglutinin?

botulinum toxin type A + hemagglutinin 是一种治疗药物,由Microgen研发。该药已获批,用于治疗相关适应症,给药途径:Intramuscular (IM) Injection。

药物档案

商品名Relatox, Relatoks
公司Microgen
给药途径Intramuscular (IM) Injection
状态Approved

治疗适应症

botulinum toxin type A + hemagglutinin 针对 5 个适应症,涉及 5 个治疗领域。

治疗领域疾病/病症分期
Eye disordersBlepharospasm✓ Approved
Skin and subcutaneous tissue disordersSkin wrinkling✓ Approved
Congenital, familial and genetic disordersCerebral palsyPhase III
Nervous system disordersMigrainePhase III
Musculoskeletal and connective tissue disordersTorticollisPhase III

相关研究文献

PubMedAesthetic plastic surgery2026-11-17

Prophylactic Intralesional Botulinum Toxin Type A Versus Triamcinolone Acetonide Followed by Combination Therapy for Keloid Prevention and Treatment in High-Risk Orthopedic Surgery Patients: A Retrospective Comparative Study.

Ahmedov Anvar A, Karabulut Furkan F, Çiçek Ali Can AC, Aksay Mehmet Fatih MF

To compare the efficacy of prophylactic intralesional botulinum toxin type A (BTX-A) versus triamcinolone acetonide (TAC) in keloid-prone patients undergoing orthopedic surgery, and to evaluate outcomes of subsequent combination therapy for those developing postoperative keloids. Seventy-four patients with documented keloid history were grouped by prophylactic agent per surgeon's routine practice: BTX-A (n = 39) and TAC (n = 35). Patients developing keloids received combined BTX-A+TAC monthly for three sessions. Outcomes included formation rates, time to formation, lesional dimensions, percentage improvements, Stony Brook Scar Evaluation Scale (SBSES) scores, complications, and recurrence. Formation rates were similar (82.1% vs. 85.7%, p = 0.670). BTX-A prophylaxis was associated with longer time to formation (8.03 ± 2.18 vs. 4.87 ± 2.76 months, p < 0.001), smaller transverse diameter (0.96 ± 1.12 vs. 1.81 ± 1.47 mm, p < 0.001), and a trend toward smaller volume (215.23 ± 613.01 vs. 570.19 ± 1542.46 mm3, p = 0.049). After combination therapy, TAC-prophylaxed patients had superior thickness (87.87 ± 4.70% vs. 79.50 ± 11.70%, p = 0.006) and volume improvement (91.00 ± 4.22% vs. 82.72 ± 11.56%, p = 0.008), and higher post-treatment SBSES scores (4.50 ± 0.68 vs. 4.00 ± 0.80, p = 0.012). All patients improved significantly (p < 0.001). Complication rates were similar (p = 0.530), with skin atrophy most frequent (46.7%). BTX-A prophylaxis was associated with longer time to keloid formation and a trend toward smaller volume, while TAC-prophylaxed patients showed enhanced response to subsequent combination therapy. Combined BTX-A+TAC appears well tolerated and potentially effective for managing keloids in high-risk surgical patients. This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

PMID 43039988
阅读全文 →
PubMedTurkish archives of pediatrics2026-11-17

Effectiveness and Safety of Surgical and Advanced Interventional Treatments for Pediatric Refractory Constipation: A Systematic Review with Domain-Specific Meta-analyses of Proportions.

Aldaz Vallejo Freddy Alexander FA, Oliveros-Rivero Jorge J, Patiño González Celeste Carolina CC

To synthesize clinical outcomes and safety of surgical and advanced interventional treatments for pediatric refractory constipation using a phenotype-directed, domain-specific approach. This systematic review with domain-specific meta-analyses of proportions followed PRISMA 2020 and was prospectively registered in PROSPERO (CRD420261378728). PubMed/MEDLINE, Embase, Scopus, Web of Science, CENTRAL, the Cochrane Library, LILACS, trial registries, Google Scholar, and reference lists were searched through April 29, 2026. Eligible interventions included antegrade continence enema (ACE) procedures, botulinum toxin injection, transanal irrigation (TAI), diversion, and selected resective or motility-guided procedures. Random-effects single-arm proportions were pooled only within clinically coherent domains; safety outcomes were synthesized structurally when definitions and denominators were not sufficiently comparable for pooling. Thirty-two primary interventional studies met final eligibility criteria, of which 22 contributed to quantitative synthesis. Descriptive pooled study-defined clinical success or response was 85% (95% CI: 81%-88%) for ACE procedures, 81% (95% CI: 72%-89%) for botulinum toxin injection, 81% (95% CI: 64%-94%) for TAI, and 91% (95% CI: 76%-100%) for resective or advanced surgery. The surgical estimate was exploratory because procedures and indications were heterogeneous. These proportions are not comparative treatment-effect estimates. Certainty of evidence was low or very low, and safety reporting was inconsistent across studies. Advanced interventions may be associated with favorable outcomes in carefully selected children with refractory constipation, but indications and risks are phenotype specific. The evidence does not support direct effectiveness comparisons between therapeutic domains.

PMID 43041032
阅读全文 →
PubMedBioinformatics advances2026-11-17

Identification and characterization of bacterial repeat-in-toxin adhesins using long-read genome analysis.

Hansen Thomas T, Graham Laurie A LA, Soares Blake P BP, Lee Daniel D et al.

Gram-negative bacteria attach to host surfaces using ligand-binding domains (LBDs) at the distal tips of fibrillar repeats-in-toxin adhesins. Blocking these initial interactions could prevent colonization, biofilm formation, and infection. To achieve this, the adhesins must be identified and, in species encoding multiple adhesins, the predominant type determined. These adhesins are often the largest proteins encoded by a genome (1500-15 000 aa) and are frequently misannotated as incomplete or pseudogene products because their repetitive sequences complicate short-read genome assemblies. Our bioinformatic pipeline collects predicted proteins from long-read assemblies and clusters them according to similarity in their C-terminal regions, where LBDs are typically located. Adhesins are identified by their size and domain architecture and modelled using AlphaFold3. Analysis of multiple strains from seven species identified 35 adhesin isoforms distributed across 16 loci, exhibiting diverse combinations of putative binding domains such as carbohydrate-binding modules and von Willebrand factor A-like domains. Similar adhesins were sometimes shared among species through common ancestry or horizontal gene transfer. Three species encoded an adhesin of unknown function that lacked an obvious LBD. The software and workflows were written in Python3 and have been made available on Zenodo.

PMID 43042075
阅读全文 →
PubMedNature reviews. Microbiology2026-11-17

Uncovering a clostridial toxin behind necrotizing enterocolitis.

Taglialegna Agustina A

PMID 43039996
阅读全文 →
PubMedGeroScience2026-11-17

Adenosine deaminase co-immunization reverses age‑associated immunosenescence by restoring germinal center T follicular helper cell function.

Bitsko Emily N EN, Joyner David R DR, Maslanka Jeffrey R JR, Woloszczuk Kyra K et al.

Older adults experience disproportionate morbidity and mortality from Clostridioides difficile infection (CDI); however, existing toxoid- and receptor binding domain (RBD)-based vaccines elicit suboptimal protection in aged hosts due to the age-associated defects in CD4+ T cell function, T follicular helper (TFH) cell activation, and antibody quality. We evaluated whether adenosine deaminase (ADA), an enzymatic immune modulator that degrades immunosuppressive adenosine, and improves GC TFH differentiation and survival, could reverse these age-related impairments when co-delivered with DNA vaccine plasmids targeting toxin A and B RBDs (pRBD). In aged mice, pRBD vaccination alone produced markedly reduced toxin-specific effector/memory CD4+ T cells, diminished TFH activation, and poor toxin A neutralization compared to vaccinated young mice. Co-immunization with plasmid-encoded adenosine deaminase-1 (pADA) restored toxin-specific CD4+ T cell generation and cytokine production, activation-induced marker (AIM) TFH responses, and antibody-mediate toxin neutralization to levels comparable to young adults. Mechanistically, pADA co-immunization was associated with the reduction of CXCR4 on germinal center (GC) TFH cells-a phenotype previously linked to impaired GC positioning and diminished B cell help in aging-suggesting that ADA may improve humoral quality through modulation of CXCR4 expression, a pathway previously associated with GC TFH positioning. These immune enhancements corresponded with improved clinical outcomes in morbidity, mortality, and weight loss following C. difficile spore challenge of aged mice. Finally, pADA significantly reduced adenosine levels in aged lymph nodes, implicating a potential enzymatic-based regulation of GC immunosenescence. Together, these findings identify ADA as a metabolic adjuvant capable of reversing key features of vaccine immunosenescence and highlight adenosine-dependent CXCR4 regulation as a tractable axis for improving vaccine efficacy in older populations.

PMID 43040063
阅读全文 →
PubMedEcotoxicology (London, England)2026-11-17

Impact of biosynthesized zinc oxide nanoparticles at environmentally relevant concentrations on the growth and toxin dynamics in the marine harmful alga Gymnodinium catenatum culture.

Mohamed Zakaria A ZA, Abohbell Hana H, Omran Adel S Ben ASB, Asseri Tahani A Y TAY et al.

Most previous studies have assessed the toxicity of engineering Zinc oxide nanoparticles rather than biosynthesized ones on the growth of aquatic microalgae. Therefore, the main objective of this study is to investigate the effects of biosynthesized ZnO NPs at concentrations of 0.05-10 mg L- 1 on the growth and toxin dynamics in batch culture of the harmful marine microalga Gymnodinium catenatum. ZnO NPs inhibited G. catenatum growth, with cell structural damage and lysis. The inhibition rate was concentration- and time-dependent, with half-maximal inhibitory concentration (IC50) values (0.24 - 0.04 mg L- 1) being within the range of environmentally relevant concentrations (0.001-1 mg L- 1). Additionally, ZnO NPs reduced cellular toxin content of G. catenatum cells, bringing levels down to a range of 0-91 pg cell⁻¹ by day 8, compared to control (109 pg cell- 1). The released extracellular toxins decreased along NP concentrations, with no detectable levels found at higher ZnO NP concentrations (2 and 10 mg L- 1) after days. This demonstrates that extracellular toxins are promptly eliminated via adsorption by ZnO NPs once released into the medium. The desorption experiment confirmed that the initial clearance of extracellular toxins from the medium of NP-treated cultures was due to adsorption to ZnO NPs. Our study highlighted the potential toxicity of biosynthesized ZnO NPs on toxic marine dinoflagellates even at environmentally relevant concentrations. On another side, their capability of toxin adsorption opens an avenue for possible application of ZnO NPs in removing algal toxins from water under controlled settings.

PMID 43040108
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多botulinum toxin type A + hemagglutinin